Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer	Novartis	Ongoing	LEE011 (Ribociclib)	3	CLEE011E2301	King Khalid University Hospital (Riyadh)_ King Faisal Specialist Hospital and Research Center (Riyadh)
International Registry to assess mEdical Practice withlOngitudinal obseRvation for Treatment of Heart Failure(REPORT-HF)	Novartis	Ongoing	N/A	4	2401	King Fahad Specialist Hospital (Dammam)
Phase IIIb, Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness & Safety of the use of Carbaglu® in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)	KAIMRC	Ongoing	Carglumic acid	3	IIT-OE-2013-001	King Abdulaziz Medical City NG (Riyadh)_ King Fahad Medical City (Riyadh)
A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes	Intarcia Therapeutics	Completed	ITCA 650	3	ITCA 650-CLP-107	King Abdulaziz Medical City NG (Jeddah)_ King Abdulaziz Hospital NG (Al Ahsa)
A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer	Bayer	Ongoing	Sorafenib	3	BAY43-9006/14295	King Faisal Specialist Hospital and Research Center (Riyadh)
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis	Mast Therapeutics	Ongoing	Purified Poloxamer 188	3	MST-188-01	King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), Maternity and Children's Hospital (Al Ahsa)_ King Fahad Medical City (Riyadh)_ King Abdulaziz University Hospital (Jeddah)
Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency	Octapharma	Ongoing	Octafibrin	3	Forma 02	King Khalid University Hospital (Riyadh)
A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer	Roche	Ongoing	Pertuzumab / Trastuzumab / Taxane	3b	MO28047	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah)
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)	AbbVie	Ongoing	ABT-450/r/ABT-267 ABT-333Ribavirin (RBV)	3b	M14-423	King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
Risk assesment and mangement of Vte in women at risk of thromboEmbolism during pregnancy and puerperium	Sanofi	Ongoing	N/A	4	OBS14159	King Abdulaziz University Hospital (Jeddah)